Linagliptin + Metformin HydrochlorideThird Party Manufacturing in India

Linagliptin + Metformin Hydrochloride is a fixed-dose combination that targets multiple pathophysiological defects of type 2 diabetes through complementary mechanisms. Linagliptin, a selective DPP-4 inhibitor, prevents the rapid degradation of incretin hormones (GLP-1 and GIP), increasing their active concentrations in the circulation. Enhanced GLP-1 activity stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, delays gastric emptying, and promotes satiety. Metformin hydrochloride, a biguanide, acts primarily by reducing hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis. It also improves peripheral insulin sensitivity by increasing glucose uptake and utilization in skeletal muscle and adipose tissue via AMP-activated protein kinase (AMPK) activation. Metformin additionally reduces intestinal glucose absorption and favorably alters the gut microbiome. By combining these two mechanisms, linagliptin enhances insulin secretion when glucose is high while metformin reduces basal hepatic glucose output and improves insulin sensitivity, providing comprehensive glycemic control with a low risk of hypoglycemia and weight neutrality.

Linagliptin + Metformin Hydrochloride third party manufacturing in India offers a convenient once-daily or twice-daily fixed-dose combination for comprehensive type 2 diabetes management. This product combines two of the most widely prescribed antidiabetic agents in a single tablet.

Therapeutic Uses

Linagliptin + Metformin Hydrochloride is prescribed for the treatment of:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise in patients inadequately controlled on metformin or linagliptin monotherapy, or in patients already controlled on the individual components.
• Dual Mechanism Glycemic Control: Provides both insulinotropic effects (linagliptin) and insulin-sensitizing effects (metformin) for comprehensive glucose management.
• HbA1c Reduction: Significantly reduces glycated hemoglobin levels more effectively than either agent alone.
• Cardiovascular Risk Management: Metformin's established cardiovascular benefits combined with linagliptin's neutral cardiovascular safety profile make this combination suitable for patients with type 2 diabetes and cardiovascular comorbidities.
• Overweight and Obese Patients: Weight-neutral profile of both agents makes this combination appropriate for patients where weight gain is a concern.

Why Choose a Linagliptin + Metformin Hydrochloride Manufacturer in India

This fixed-dose combination simplifies treatment regimens by reducing pill burden, which directly improves patient adherence. For pharmaceutical brands, offering a linagliptin-metformin combination fills a key gap in the DPP-4 inhibitor segment of the diabetes portfolio. NOTE: The listed strength "1mg" for Metformin Hydrochloride appears to be a data entry error — Metformin is clinically dosed at 500mg or higher. The product has been configured with the standard strength "2.5mg + 500mg". Please verify the intended formulation strength with the product team before finalizing. Indian WHO-GMP certified manufacturers provide competitive pricing, regulatory support, and reliable supply chains for this growing therapeutic category across both domestic and export markets.